Black Diamond Therapeutics, Inc.
Develops precision oncology drugs targeting mutation families in lung and brain cancers.
BDTX | US
Overview
Corporate Details
- ISIN(s):
- US09203E1055
- LEI:
- Country:
- United States of America
- Address:
- ONE MAIN STREET, 14TH FLOOR, 2142 CAMBRIDGE
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Black Diamond Therapeutics, Inc. is a clinical-stage precision oncology company that develops MasterKey therapies for patients with genetically defined cancers. Leveraging its proprietary Mutation-Allostery-Pharmacology (MAP) platform, the company discovers and develops small molecule therapies designed to target families of oncogenic mutations. This 'one solution for many mutations' approach aims to address broad patient populations, overcome drug resistance, and minimize toxicities. The company's pipeline is focused on treatments for non-small cell lung cancer (NSCLC) and glioblastoma (GBM), with therapies designed to be brain-penetrant to treat central nervous system diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Black Diamond Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Black Diamond Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Black Diamond Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
